Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC
Published on 16 April 2026
Dr Miranda Gogishvili speaks to ecancer about the 6-year follow-up results from the EMPOWER-Lung 1 trial.
The study looked at long-term outcomes with first-line cemiplimab monotherapy in patients with advanced non-small cell lung cancer and high PD-L1 expression.
Cemiplimab demonstrated improvements in overall survival, progression-free survival, and response rates vs chemotherapy.
Outcomes were particularly notable among patients with very high PD-L1 expression and those who completed the full course of treatment.
Grade 3 or higher treatment-emergent adverse events occurred in 45.8% of patients treated with cemiplimab compared with 51.6% with chemotherapy.
Dr Gogishvili notes that these results reinforce the long-term benefit-risk profile of cemiplimab as a first-line treatment option in this patient population.